Wuhan Hiteck Biological Pharma Co (SZSE:300683) Debt-to-Equity : 0.02 (As of Jun. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Wuhan Hiteck Biological Pharma Co Debt-to-Equity?

Wuhan Hiteck Biological Pharma Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was ¥30.7 Mil. Wuhan Hiteck Biological Pharma Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was ¥27.0 Mil. Wuhan Hiteck Biological Pharma Co's Total Stockholders Equity for the quarter that ended in Jun. 2024 was ¥2,455.5 Mil. Wuhan Hiteck Biological Pharma Co's debt to equity for the quarter that ended in Jun. 2024 was 0.02.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Wuhan Hiteck Biological Pharma Co's Debt-to-Equity or its related term are showing as below:

SZSE:300683' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.02 Max: 0.05
Current: 0.02

During the past 11 years, the highest Debt-to-Equity Ratio of Wuhan Hiteck Biological Pharma Co was 0.05. The lowest was 0.00. And the median was 0.02.

SZSE:300683's Debt-to-Equity is ranked better than
92.72% of 838 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs SZSE:300683: 0.02

Wuhan Hiteck Biological Pharma Co Debt-to-Equity Historical Data

The historical data trend for Wuhan Hiteck Biological Pharma Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wuhan Hiteck Biological Pharma Co Debt-to-Equity Chart

Wuhan Hiteck Biological Pharma Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.01

0.05

0.04

0.03

Wuhan Hiteck Biological Pharma Co Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Debt-to-Equity	Get a 7-Day Free Trial															0.02	0.02	0.03	0.03	0.02

Competitive Comparison of Wuhan Hiteck Biological Pharma Co's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Wuhan Hiteck Biological Pharma Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Wuhan Hiteck Biological Pharma Co's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Wuhan Hiteck Biological Pharma Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Wuhan Hiteck Biological Pharma Co's Debt-to-Equity falls into.

Wuhan Hiteck Biological Pharma Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Wuhan Hiteck Biological Pharma Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(29.235	+	36.721)	/	2478.155
	=	0.03

Wuhan Hiteck Biological Pharma Co's Debt to Equity Ratio for the quarter that ended in Jun. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(30.684	+	27.037)	/	2455.529
	=	0.02

Wuhan Hiteck Biological Pharma Co (SZSE:300683) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Wuhan Hiteck Biological Pharma Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Wuhan Hiteck Biological Pharma Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Wuhan Hiteck Biological Pharma Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Wuhan Hiteck Biological Pharma Co Ltd (SZSE:300683) » Definitions » Debt-to-Equity

Traded in Other Exchanges

N/A

Address

Hite Science and Technology Park, Wuhan Economic and Technological Development Zone, Hubei Province, Wuhan, CHN, 430056

Website

http://www.hiteck.com.cn

Wuhan Hiteck Biological Pharma Co Ltd is a biopharmaceutical manufacturing enterprise in China. The company is primarily engaged in the development, production and sale of biological products. Its product portfolio comprises rat nerve growth factor freeze-dried powder injection, injection of anti-hepatitis B transfer factor freeze-dried powder injection, thrombin and other chemicals. The company also has more than 20 kinds of products such as hepatitis B treatment drug op Heparin and hemostatic agent thrombin.

Executives

Yan Jie	Director
Li Sheng Qiang	Executives

Wuhan Hiteck Biological Pharma Co Headlines

No Headlines